Berlana, D., et al., Use of colistin in the treatment of multiple-drug-resistant
gram-negative infections. Am J Health Syst Pharm, 2005. 62(1): 39-47.
Blot, S., et al., Nosocomial bacteremia caused by antibiotic-resistant gramnegative
bacteria in critically ill patients: clinical outcome and length of
hospitalization. Clin Infect Dis, 2002. 34(12): 1600-6.
Bosso, J.A., C.A. Liptak, D.K. Seilheimer, G.M. Harrison, Toxicity of colistin
in cystic fibrosis patients. DICP, 1991. 25: 1168-70.
Boucher, H.W., et al., Bad bugs, no drugs: no ESKAPE! An update from
the Infect Diseases Soc of America. Clin Infect Dis, 2009. 48(1): 1-12.
Conway, S.P., M.N. Pond, A. Watson, C. Etherington, H. Robey, M.H.
Goldman, Intravenous colistin sulphomethate in acute respiratory exacerbations
in adult patients with cystic fibrosis. Thorax, 1997. 52: 987-93.
Giske C., et al., Clinical and economic impact of common multidrug-resistant
... Antimicrob Agents Chemother, 2008. 52(3): 813-21.
Harris T., et al., Cohort study of effect of being overweight and change in
weight on risk of coronary heart disease in old age. BMJ, 1997. 314(7097):
-4.
Hsu, L.Y., et al., Surveillance and correlation of antibiotic prescription
and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob
Agents Chemother, 2010. 54(3): 1173-8.
Kelly, W.N., Pharmacy: What It Is and How It Works, Third Edition. 2011:
Taylor & Francis.
Lebanova, H., D. Manolov, I. Getov, Patients' attitude about generics -
Bulgarian perspective. Marmara Pharmaceutical Journal, 2011. 16: 36-40.
Ledson, M.J., et al., Four years' experience of intravenous colomycin in
an adult cystic fibrosis unit. Eur Respir J, 1998. 12(3): 592-4.
Li, J., et al., Evaluation of colistin as an agent against multi-resistant Gramnegative
bacteria. Int J Antimicrob Agents, 2005. 25(1): 11-25.
Linden, P.K., et al., Use of parenteral colistin for the treatment of serious
infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin
Infect Dis, 2003. 37(11): e154-60.
Livermore, D.M., Multiple mechanisms of antimicrobial resistance in
Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis, 2002.
(5): 634-40.
Mauldin, P.D., et al., Attributable hospital cost and length of stay associated
with health care-associated infections caused by antibiotic-resistant gramnegative
bacteria. Antimicrob Agents Chemother, 2010. 54(1): 109-15.
Nordmann, A.J., et al., Meta-analysis comparing Mediterranean to low-fat
diets for modification of cardiovascular risk factors. American Journal of
Medicine, 2011. 124(9): 841-51 e2.
Shorr, A.F., Review of studies of the impact on Gram-negative bacterial
resistance on outcomes in the intensive care unit. Crit Care Med, 2009.
(4): 1463-9.
Slama, T.G., Gram-negative antibiotic resistance: there is a price to pay.
Crit Care, 2008. 12 Suppl 4: S4.
Арнаудова, П., Нова медицинска и етиономна терминология. 2005,
София: Медицина и Физкултура.
Георгиев, Б. и Ц. Танкова, Подходи за намаляване на сърдечно-съдовия
риск при захарен диабет. Наука Ендокринология, 2008. 1(1): 32-38.
Йорданов, Й., Антропология на населението на България в края на
XX век. 2006, София: БАН.
Томова, А., Затлъстяването – проблемът и подходът към решението
му. Наука Ендокринология, 2008. 1(1): 42-46.
